Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer

Inclusion Criteria: * The subject must be ≥ 18 years old on the day of consent. * The subject is able to understand written and spoken English. * The patient must have histologically or cytologically confirmed prostate adenocarcinoma. * The subject must have castration-resistant prostate cancer (CRPC). * The subject must have metastatic disease involving bone, seen on radiographic imaging (bone scan, CT scan, PET scan, or MRI). * The subject must be in a castrate state (e.g., currently receiving androgen deprivation therapy or have had an orchiectomy). * The subject must be starting any line of systemic treatment post-androgen deprivation/antiandrogen therapy, with any of the following: chemotherapy (e.g., docetaxel, paclitaxel, carboplatin, cabazitaxel, or mitoxantrone); abiraterone acetate; MDV3100; ketoconazole; a clinical trial. * The subject owns or has regular access to a telephone (cellular or land line). * The subject is willing and able to self-report pain and analgesic use via an automated telephone system. * The subject is willing and able to provide informed consent. Exclusion Criteria: * The subject has small cell or predominantly neuroendocrine differentiated prostate tumor.